REGN · News · 20260808N

Revenue Performance and Mix

REGENERON PHARMACEUTICALS, INC. · 2026-08-08 · Importance 24 · Surprise 14

Regeneron reported Q2 2026 revenue of $4.29 billion, exceeding analyst expectations. Diluted EPS was $14.29 for the quarter. Revenue increased year over year, while net income and diluted EPS declined sequentially or year over year, according to the report. The mixed results reflected higher sales alongside softer profitability.

Key facts

• PensionDanmark increased its stake in Regeneron by 17.6% in the second quarter, acquiring 3,619 additional shares and now owning 24,190 shares valued at approximately $15.1 million. source